Effects of hypoxia on tumor metabolism

Cancer and Metastasis Reviews

Volumn 26, Issue 2, 2007, Pages 291-298

  Kim, Jung Whan ^a   Gao, Ping ^a   Dang, Chi V ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Hypoxia; Hypoxia inducible factor; Metabolism; Tumor; Tumor bioenergetic

Indexed keywords

GLUCOSE 6 PHOSPHATE ISOMERASE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PHOSPHOGLUCOMUTASE; REACTIVE OXYGEN METABOLITE;

ACIDIFICATION; ACIDITY; BIOENERGY; CANCER; CANCER THERAPY; CELL AGING; CELL GROWTH; CELL METABOLISM; CELL SURVIVAL; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HYPOXIA; LIPID METABOLISM; MICROENVIRONMENT; MITOCHONDRIAL RESPIRATION; MOLECULAR MECHANICS; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TUMOR CELL; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

ANIMALS; CELL HYPOXIA; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MITOCHONDRIA; MODELS, BIOLOGICAL; NEOPLASMS; OXYGEN CONSUMPTION; REACTIVE OXYGEN SPECIES;

EID: 34547130302     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9060-4     Document Type: Review

References (114)

1. Hochachka, P. W. (1998). Mechanism and evolution of hypoxia-tolerance in humans. Journal of Experimental Biology, 201, 1243-1254.
2. Semenza, G. L. (1999). Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annual Review of Cell and Developmental Biology, 15, 551-578.
3. Giatromanolaki, A., & Harris, A. L. (2001). Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. Anticancer Research, 21, 4317-4324.
4. Semenza, G. L. (2000). Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Critical Reviews in Biochemistry and Molecular Biology, 35, 71-103.
5. Semenza, G. L., Roth, P. H., Fang, H. M., & Wang, G. L. (1994). Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. Journal of biological chemistry, 269, 23757-23763.
6. Wang, G. L., & Semenza, G. L. (1993). General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 90, 4304-4308.
7. Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., et al. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and cellular biology, 16, 4604-4613.
8. Gordan, J. D., & Simon, M. C. (2007). Hypoxia-inducible factors: Central regulators of the tumor phenotype. Current Opinion in Genetics & Development, 17, 71-77.
9. Semenza, G. L. (2001). HIF-1, O(2), and the 3 PHDs: How animal cells signal hypoxia to the nucleus. Cell, 107, 1-3.
10. Semenza, G. L. (2004). Hydroxylation of HIF-1: Oxygen sensing at the molecular level. Physiology (Bethesda), 19, 176-182.
11. Schofield, C. J., & Ratcliffe, P. J. (2004). Oxygen sensing by HIF hydroxylases. Nature Reviews. Molecular Cell Biology, 5, 343-354.
12. Krek, W. (2000). VHL takes HIF's breath away. Nature Cell Biology, 2, E121-E123.
13. Jaakkola, P., Mole, D. R., Tian, Y. M., Wilson, M. I., Gielbert, J., Gaskell, S. J., et al. (2001). Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 292, 468-472.
14. Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T. Y., Huang, L. E., et al. (2000). Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nature Cell Biology, 2, 423-427.
15. Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., et al. (1998). Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature, 394, 485-490.
16. Liu, L., & Simon, M. C. (2004). Regulation of transcription and translation by hypoxia. Cancer Biology & Therapy, 3, 492-497.
17. Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Reviews Cancer, 3, 721-732.
18. Ryan, H. E., Lo, J., & Johnson, R. S. (1998). HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO Journal, 17, 3005-3015.
19. Fei, P., Wang, W., Kim, S. H., Wang, S., Burns, T. F., Sax, J. K., et al. (2004). Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell, 6, 597-609.
20. Hammond, E. M., & Giaccia, A. J. (2005). The role of p53 in hypoxia-induced apoptosis. Biochemical and Biophysical Research Communications, 331, 718-725.
21. Kim, J. W., & Dang, C. V. (2006). Cancer's molecular sweet tooth and the Warburg effect. Cancer Research, 66, 8927-8930.
22. Bardos, J. I., & Ashcroft, M. (2004). Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays, 26, 262-269.
23. Semenza, G. L., Shimoda, L. A., & Prabhakar, N. R. (2006). Regulation of gene expression by HIF-1. Novartis Foundation symposium, 272, 2-8; discussion 8-14, 33-36.
24. Semenza, G. L., Jiang, B. H., Leung, S. W., Passantino, R., Concordet, J. P., Maire, P., et al. (1996). Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. Journal of Biological Chemistry, 271, 32529-32537.
25. Fantin, V. R., St-Pierre, J., & Leder, P. (2006). Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 9, 425-434.
26. Balaban, R. S., Nemoto, S., & Finkel, T. (2005). Mitochondria, oxidants, and aging. Cell, 120, 483-495.
27. Kondoh, H., Lleonart, M. E., Gil, J., Wang, J., Degan, P., Peters, G., et al. (2005). Glycolytic enzymes can modulate cellular life span. Cancer Research, 65, 177-185.
28. Welford, S. M., Bedogni, B., Gradin, K., Poellinger, L., Broome Powell, M., & Giaccia, A. J. (2006). HIF1alpha delays premature senescence through the activation of MIF. Genes & Development, 20, 3366-3371.
29. Maity, A., & Koumenis, C. (2006). HIF and MIF-a nifty way to delay senescence? Genes & development, 20, 3337-3341.
30. Kaelin, W. G. (2005). ROS: Really involved in oxygen sensing. Cell Metabolism, 1, 357-358.
31. Guzy, R. D., Hoyos, B., Robin, E., Chen, H., Liu, L., Mansfield, K. D., et al. (2005). Mitochondrial complex III is required for hypoxia-induced ROS and cellular oxygen sensing. Cell Metabolism, 1, 401-408.
32. Brunelle, J. K., Bell, E. L., Quesada, N. M., Vercauteren, K., Tiranti, V., Zeviani, M., et al. (2005). Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metabolism, 1, 409-414.
33. Cairns, R., Papandreou, I., & Denko, N. (2006). Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Molecular Cancer Research, 4, 61-70.
34. Bacon, A. L., & Harris, A. L. (2004). Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Annals of Medicine, 36, 530-539.
35. Wykoff, C. C., Beasley, N. J., Watson, P. H., Turner, K. J., Pastorek, J., Sibtain, A., et al. (2000). Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Research, 60, 7075-7083.
36. Svastova, E., Hulikova, A., Rafajova, M., Zat'ovicova, M., Gibadulinova, A., Casini, A., et al. (2004). Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS letters, 577, 439-445.
37. Robertson, N., Potter, C., & Harris, A. L. (2004). Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Research, 64, 6160-6165.
38. Potter, C., & Harris, A. L. (2004). Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle, 3, 164-167.
39. Supuran, C. T., Scozzafava, A., & Casini, A. (2003). Carbonic anhydrase inhibitors. Medicinal Research Reviews, 23, 146-189.
40. Potter, C. P., & Harris, A. L. (2003). Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. British Journal of Cancer, 89, 2-7.
41. Holness, M. J., & Sugden, M. C. (2003). Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochemical Society Transactions, 31, 1143-1151.
42. Kim, J. W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006). HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism, 3, 177-185.
43. Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006). HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metabolism, 3, 187-197.
44. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Gatter, K. C., & Harris, A. L. (2005). Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. Neoplasia, 7, 1-6.
45. Fukuda, R., Zhang, H., Kim, J. W., Shimoda, L., Dang, C. V., & Semenza, G. L. (2007). HIF-1 regulates cytochrome oxidase subunit composition to optimize the efficiency of respiration in hypoxic cells. Cell, (in press).
46. Poyton, R. O. (1999). Models for oxygen sensing in yeast: Implications for oxygen-regulated gene expression in higher eucaryotes. Respiration Physiology, 115, 119-133.
47. Burke, P. V., & Poyton, R. O. (1998). Structure/function of oxygen-regulated isoforms in cytochrome c oxidase. Journal of Experimental Biology, 201, 1163-1175.
48. Kwast, K. E., Burke, P. V., & Poyton, R. O. (1998). Oxygen sensing and the transcriptional regulation of oxygen-responsive genes in yeast. Journal of Experimental Biology, 201, 1177-1195.
49. Tian, H., McKnight, S. L., & Russell, D. W. (1997). Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes & Development, 11, 72-82.
50. Card, P. B., Erbel, P. J., & Gardner, K. H. (2005). Structural basis of ARNT PAS-B dimerization: Use of a common beta-sheet interface for hetero- and homodimerization. Journal of Molecular Biology, 353, 664-677.
51. Appelhoff, R. J., Tian, Y. M., Raval, R. R., Turley, H., Harris, A. L., Pugh, C. W., et al. (2004). Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. Journal of Biological Chemistry, 279, 38458-38465.
52. Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B., & Simon, M. C. (2003). Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Molecular and Cellular Biology, 23, 9361-9374.
53. Warnecke, C., Zaborowska, Z., Kurreck, J., Erdmann, V. A., Frei, U., Wiesener, M., et al. (2004). Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: Erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB Journal, 18, 1462-1464.
54. Covello, K. L., Kehler, J., Yu, H., Gordan, J. D., Arsham, A. M., Hu, C. J., et al. (2006). HIF-2alpha regulates Oct-4: Effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes & Development, 20, 557-570.
55. Aprelikova, O., Wood, M., Tackett, S., Chandramouli, G. V., & Barrett, J. C. (2006). Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. Cancer Research, 66, 5641-5647.
56. Maranchie, J. K., & Zhan, Y. (2005). Nox4 is critical for hypoxia-inducible factor 2-alpha transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma. Cancer Research, 65, 9190-9193.
57. Seagroves, T., & Johnson, R. S. (2002). Two HIFs may be better than one. Cancer Cell, 1, 211-213.
58. Acker, T., Diez-Juan, A., Aragones, J., Tjwa, M., Brusselmans, K., Moons, L., et al. (2005). Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell, 8, 131-141.
59. Covello, K. L., Simon, M. C., & Keith, B. (2005). Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Research, 65, 2277-2286.
60. Kim, W. Y., Safran, M., Buckley, M. R., Ebert, B. L., Glickman, J., Bosenberg, M., et al. (2006). Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO Journal, 25, 4650-4662.
61. Sowter, H. M., Raval, R. R., Moore, J. W., Ratcliffe, P. J., & Harris, A. L. (2003). Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Research, 63, 6130-6134.
62. Kuhajda, F. P. (2006). Fatty acid synthase and cancer: New application of an old pathway. Cancer Research, 66, 5977-5980.
63. Menendez, J. A., Vellon, L., Oza, B. P., & Lupu, R. (2005). Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene. Journal of Cellular Biochemistry, 94, 857-863.
64. Menendez, J. A., Decker, J. P., & Lupu, R. (2005). In support of fatty acid synthase (FAS) as a metabolic oncogene: Extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. Journal of Cellular Biochemistry, 94, 1-4.
65. Baron, A., Migita, T., Tang, D., & Loda, M. (2004). Fatty acid synthase: A metabolic oncogene in prostate cancer? Journal of Cellular Biochemistry, 91, 47-53.
66. Pizer, E. S., Wood, F. D., Heine, H. S., Romantsev, F. E., Pasternack, G. R., & Kuhajda, F. P. (1996). Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Research, 56, 1189-1193.
67. Pizer, E. S., Jackisch, C., Wood, F. D., Pasternack, G. R., Davidson, N. E., & Kuhajda, F. P. (1996). Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Research, 56, 2745-2747.
68. Alli, P. M., Pinn, M. L., Jaffee, E. M., McFadden, J. M., & Kuhajda, F. P. (2005). Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene, 24, 39-46.
69. Plas, D. R., & Thompson, C. B. (2005). Akt-dependent transformation: There is more to growth than just surviving. Oncogene, 24, 7435-7442.
70. Gottlieb, E., & Thompson, C. B. (2003). Targeting the mitochondria to enhance tumor suppression. Methods in Molecular Biology, 223, 543-554.
71. Bui, T., & Thompson, C. B. (2006). Cancer's sweet tooth. Cancer Cell, 9, 419-420.
72. Elstrom, R. L., Bauer, D. E., Buzzai, M., Karnauskas, R., Harris, M. H., Plas, D. R., et al. (2004). Akt stimulates aerobic glycolysis in cancer cells. Cancer Research, 64, 3892-3899.
73. Li, F., Wang, Y., Zeller, K. I., Potter, J. J., Wonsey, D. R., O'Donnell, K. A., et al. (2005). Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Molecular and Cellular Biology, 25, 6225-6234.
74. Hatzivassiliou, G., Zhao, F., Bauer, D. E., Andreadis, C., Shaw, A. N., Dhanak, D., et al. (2005). ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 8, 311-321.
75. Bauer, D. E., Hatzivassiliou, G., Zhao, F., Andreadis, C., & Thompson, C. B. (2005). ATP citrate lyase is an important component of cell growth and transformation. Oncogene, 24, 6314-6322.
76. Pugh, C. W., & Ratcliffe, P. J. (2003). The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1). degradation, and cancer pathogenesis. Seminars in Cancer Biology, 13, 83-89.
77. Kaelin, W. G., Jr. (2002). Molecular basis of the VHL hereditary cancer syndrome. Nature Reviews Cancer, 2, 673-682.
78. Clifford, S. C., & Maher, E. R. (2001). Von Hippel-Lindau disease: clinical and molecular perspectives. Advances in Cancer Research, 82, 85-105.
79. Zelzer, E., Levy, Y., Kahana, C., Shilo, B. Z., Rubinstein, M., & Cohen, B. (1998). Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO Journal, 17, 5085-5094.
80. Jiang, B. H., Agani, F., Passaniti, A., & Semenza, G. L. (1997). V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1). and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. Cancer Research, 57, 5328-5335.
81. Karni, R., Dor, Y., Keshet, E., Meyuhas, O., & Levitzki, A. (2002). Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia. Journal of Biological Chemistry, 277, 42919-42925.
82. Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., & Maity, A. (2001). Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. Journal of Biological Chemistry, 276, 9519-9525.
83. Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z., Hunter, T., & Vogt, P. K. (2001). Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth & Differentiation, 12, 363-369.
84. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001). HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Molecular and Cellular Biology, 21, 3995-4004.
85. Brugarolas, J., & Kaelin, W. G., Jr. (2004). Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell, 6, 7-10.
86. Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., et al. (2004). Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes & Development, 18, 2893-2904.
87. Brugarolas, J. B., Vazquez, F., Reddy, A., Sellers, W. R., & Kaelin, W. G., Jr. (2003). TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell, 4, 147-158.
88. Gottlieb, E., & Tomlinson, I. P. (2005). Mitochondrial tumour suppressors: A genetic and biochemical update. Nature Reviews. Cancer, 5, 857-866.
89. Astuti, D., Latif, F., Dallol, A., Dahia, P. L., Douglas, F., George, E., et al. (2001). Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. American Journal of Human Genetics, 69, 49-54.
90. Gimm, O., Armanios, M., Dziema, H., Neumann, H. P., & Eng, C. (2000). Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Research, 60, 6822-6825.
91. Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., et al. (2000). Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 287, 848-851.
92. Eng, C., Kiuru, M., Fernandez, M. J., & Aaltonen, L. A. (2003). A role for mitochondrial enzymes in inherited neoplasia and beyond. Nature Reviews. Cancer, 3, 193-202.
93. Brandon, M., Baldi, P., & Wallace, D. C. (2006). Mitochondrial mutations in cancer. Oncogene, 25, 4647-4662.
94. Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., et al. (2005). Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85.
95. Gatenby, R. A., & Gillies, R. J. (2004). Why do cancers have high aerobic glycolysis? Nature Reviews. Cancer, 4, 891-899.
96. Warburg, O. (1956). On respiratory impairment in cancer cells. Science, 124, 269-270.
97. Warburg, O. (1956). On the origin of cancer cells. Science, 123, 309-314.
98. Shim, H., Dolde, C., Lewis, B. C., Wu, C. S., Dang, G., Jungmann, R. A., et al. (1997). c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth. Proceedings of the National Academy of Sciences of the United States of America, 94, 6658-6663.
99. Osthus, R. C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., et al. (2000). Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. Journal of Biological Chemistry, 275, 21797-21800.
100. Kim, J. W., Zeller, K. I., Wang, Y., Jegga, A. G., Aronow, B. J., O'Donnell, K. A., et al. (2004). Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Molecular and Cellular Biology, 24, 5923-5936.
101. Rathmell, J. C., Fox, C. J., Plas, D. R., Hammerman, P. S., Cinalli, R. M., & Thompson, C. B. (2003). Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Molecular and Cellular Biology, 23, 7315-7328.
102. Gottlob, K., Majewski, N., Kennedy, S., Kandel, E., Robey, R. B., & Hay, N. (2001). Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes & Development, 15, 1406-1418.
103. Majewski, N., Nogueira, V., Robey, R. B., & Hay, N. (2004). Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Molecular and Cellular Biology, 24, 730-740.
104. Plas, D. R., Talapatra, S., Edinger, A. L., Rathmell, J. C., & Thompson, C. B. (2001). Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. Journal of Biological Chemistry, 276, 12041-12048.
105. Corcoran, C. A., Huang, Y., & Sheikh, M. S. (2006). The regulation of energy generating metabolic pathways by p53. Cancer Biology & Therapy, 5, 1610-1613.
106. Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N., Nakano, K., Bartrons, R., et al. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 126, 107-120.
107. Green, D. R., & Chipuk, J. E. (2006). p53 and metabolism: Inside the TIGAR. Cell, 126, 30-32.
108. Kruse, J. P., & Gu, W. (2006). p53 aerobics: The major tumor suppressor fuels your workout. Cell Metabolism, 4, 1-3.
109. Assaily, W., & Benchimol, S. (2006). Differential utilization of two ATP-generating pathways is regulated by p53. Cancer Cell, 10, 4-6.
110. Matoba, S., Kang, J. G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., Hurley, P. J., Bunz, F., & Hwang, P. M. (2006). p53 regulates mitochondrial respiration. Science, 312, 1650-1653.
111. Rider, M. H., Bertrand, L., Vertommen, D., Michels, P. A., Rousseau, G. G., & Hue, L. (2004). 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: Head-to-head with a bifunctional enzyme that controls glycolysis. Biochemical Journal, 381, 561-579.
112. Perez, J. X., Roig, T., Manzano, A., Dalmau, M., Boada, J., Ventura, F., et al. (2000). Overexpression of fructose 2,6-bisphosphatase decreases glycolysis and delays cell cycle progression. American Journal of Physiology Cell Physiology, 279, C1359-C1365.
113. Gatenby, R. A., & Gawlinski, E. T. (2003). The glycolytic phenotype in carcinogenesis and tumor invasion: Insights through mathematical models. Cancer Research, 63, 3847-3854.
114. Mandelkern, M., & Raines, J. (2002). Positron emission tomography in cancer research and treatment. Technology in Cancer Research & Treatment, 1, 423-439.